1. Home
  2. AKTX vs ZVIA Comparison

AKTX vs ZVIA Comparison

Compare AKTX & ZVIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKTX
  • ZVIA
  • Stock Information
  • Founded
  • AKTX N/A
  • ZVIA 2007
  • Country
  • AKTX United States
  • ZVIA United States
  • Employees
  • AKTX N/A
  • ZVIA N/A
  • Industry
  • AKTX Biotechnology: Pharmaceutical Preparations
  • ZVIA Beverages (Production/Distribution)
  • Sector
  • AKTX Health Care
  • ZVIA Consumer Staples
  • Exchange
  • AKTX Nasdaq
  • ZVIA Nasdaq
  • Market Cap
  • AKTX 35.7M
  • ZVIA 204.8M
  • IPO Year
  • AKTX N/A
  • ZVIA 2021
  • Fundamental
  • Price
  • AKTX $1.08
  • ZVIA $2.96
  • Analyst Decision
  • AKTX
  • ZVIA Hold
  • Analyst Count
  • AKTX 0
  • ZVIA 2
  • Target Price
  • AKTX N/A
  • ZVIA $3.38
  • AVG Volume (30 Days)
  • AKTX 22.7K
  • ZVIA 1.2M
  • Earning Date
  • AKTX 08-18-2025
  • ZVIA 08-06-2025
  • Dividend Yield
  • AKTX N/A
  • ZVIA N/A
  • EPS Growth
  • AKTX N/A
  • ZVIA N/A
  • EPS
  • AKTX N/A
  • ZVIA N/A
  • Revenue
  • AKTX N/A
  • ZVIA $154,273,000.00
  • Revenue This Year
  • AKTX N/A
  • ZVIA $5.70
  • Revenue Next Year
  • AKTX N/A
  • ZVIA $6.76
  • P/E Ratio
  • AKTX N/A
  • ZVIA N/A
  • Revenue Growth
  • AKTX N/A
  • ZVIA N/A
  • 52 Week Low
  • AKTX $0.85
  • ZVIA $0.73
  • 52 Week High
  • AKTX $4.40
  • ZVIA $4.99
  • Technical
  • Relative Strength Index (RSI)
  • AKTX 41.09
  • ZVIA 49.50
  • Support Level
  • AKTX $1.10
  • ZVIA $2.60
  • Resistance Level
  • AKTX $1.15
  • ZVIA $3.04
  • Average True Range (ATR)
  • AKTX 0.03
  • ZVIA 0.25
  • MACD
  • AKTX 0.00
  • ZVIA -0.06
  • Stochastic Oscillator
  • AKTX 10.00
  • ZVIA 33.96

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

About ZVIA Zevia PBC

Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.

Share on Social Networks: